Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 11/20 | 0.48 |
| ▸ | FNTB | P49356 | 11/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053022 | 0.91 | FNTA (0.50) | BACE1CTSDFNTAFNTBPGGT1B | |
| SCHEMBL30052935 | 0.90 | BACE1 (0.48) | BACE1CTSDFNTAFNTBPGGT1B | |
| SCHEMBL30052493 | 0.90 | FNTA (0.55) | BACE1FNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL30051570 | 0.89 | FOLH1 (0.52) | FNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL30051771 | 0.89 | ENPEP (0.42) | BACE1CTSDFNTAFNTBPGGT1B | |
| SCHEMBL29714709 | 0.88 | FOLH1 (0.55) | BACE1CTSDFNTAFNTBPGGT1B | |
| SCHEMBL30272510 | 0.87 | FNTA (0.52) | BACE1CTSDFNTAFNTB | |
| SCHEMBL30053195 | 0.87 | CTSD (0.47) | BACE1CTSDFNTAFNTBPGGT1B | |
| SCHEMBL30051216 | 0.87 | FNTA (0.46) | BACE1CTSDFNTAFNTBPGGT1B | |
| SCHEMBL31372921 | 0.86 | FOLH1 (0.55) | FNTAFNTBPGGT1BFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250042969-A1 | ANTIGEN DISCOVERY FOR T CELL RECEPTORS ISOLATED FROM PATIENT TUMORS RECOGNIZING WILD-TYPE ANTIGENS AND POTENT PEPTIDE MIMOTOPES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-02-06 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | BACE1 252/4885CTSD 503/4885FNTA 734/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | BACE1 588/4885CTSD 213/4885FNTA 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.